TCM
YMAB

Tekla Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Tekla Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-197,820
Closed -$6.69M – 195
2021
Q2 		$6.69M Hold
197,820
– – 0.22% 104
2021
Q1 		$5.98M Buy
197,820
+121,272
+158% +$4.97M 0.21% 106
2020
Q4 		$3.79M Hold
76,548
– – 0.13% 134
2020
Q3 		$2.94M Hold
76,548
– – 0.11% 134
2020
Q2 		$3.31M Hold
76,548
– – 0.13% 131
2020
Q1 		$2M Buy
76,548
+65,222
+576% +$1.89M 0.09% 133
2019
Q4 		$354K Buy
+11,326
New +$335K 0.01% 200

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Tekla Capital Management's YMAB Position: Q3 2021 in Review

Tekla Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2021, closing a stake of 197,820 shares — an estimated $6.69M sold.

Tekla Capital Management first reported a position in YMAB in Q4 2019 and held it in 7 quarters. The position peaked at $6.69M in Q2 2021. 97 funds tracked by Wall St. Rank hold YMAB as of Q3 2021.

  • Tekla Capital Management reported no remaining Y-mAbs Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tekla Capital Management sold 197,820 Y-mAbs Therapeutics shares in Q3 2021, an estimated $6.69M.
  • Tekla Capital Management first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 7 quarters.
  • Tekla Capital Management's Y-mAbs Therapeutics position peaked at $6.69M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.